EVENTS & MEDIA
IN THE NEWS
February 2020 | News
2019: A Transformative Year for Avara, Paving the Way for a Strong 2020.
In 2019, Avara refocused the business on its core capabilities within Oral Solid Dose and Sterile and this resulted in an annual EBITDA of $30.7M (unaudited), at 15% on revenues of $203M, with positive contributions from every Avara facility.
Avara Pharmaceutical Services, Inc.
3300 Marshall Avenue
Norman, OK 73072
© 2020 Avara Pharmaceutical Services, Inc.
All Rights Reserved